Clinical Trial Update: A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer [Phase 2]

View source ↗

Summary

A phase II trial evaluating the combination of bevacizumab and erlotinib in patients with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Leiomyomatosis and Renal Cell Cancer
• Papillary Renal Cell Carcinoma Sporadic

Drugs mentioned

• Avastin (bevacizumab)
• Tarceva (erlotinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: HLRCC, Sporadic Papillary Renal Cell Cancer | Phase 2 | Status: COMPLETED | Results posted: 2023-08-01